{"entity":{"id":"nct03977233","kind":"trial","name":"Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of cAPOX (capecitabine, oxaliplatin), fLOT (5-FU, leucovorin, oxaliplatin, docetaxel), irinotecan (and liposomal irinotecan) and fluorouracil (5-FU) in pancreatic cancer, run by UNC Lineberger Comprehensive Cancer Center, now recruiting.","summary":"Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer is a phase 2, interventional study registered as NCT03977233 by UNC Lineberger Comprehensive Cancer Center, with a registry enrolment figure of 45 participants, started 2019-06-12 and due to reach its primary completion in 2027-07. Interventions recorded: Oxaliplatin; Leucovorin; Irinotecan Hydrochloride; 5-FU. Conditions listed: Pancreatic Ductal Adenocarcinoma (PDAC); Cancer of Pancreas; Pancreatic Cancer, Adult; Pancreas Adenocarcinoma; Pancreatic Neoplasms; Pancreatic Cancer Non-resectable; Pancreatic Cancer Resectable. Primary outcome: Best disease control rate by Pancreatic ductal adenocarcinoma (PDAC) subtype. Pancreatic eligibility wording from the registry: \"* Histologically or cytologically confirmed adenocarcinoma of the pancreas with no evidence of distant metastatic disease\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT03977233","url":"https://clinicaltrials.gov/study/NCT03977233"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy","topoisomerase-inhibitors"],"targets":[],"drugs":["capox","flot","irinotecan","fluorouracil"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03977233","phase":"2","setting":"Impact of Tumor and Stromal Subtypes on Efficacy of Neoadjuvant FOLFIRINOX in Subjects With Non-Metastatic Pancreatic Cancer","sponsor":"UNC Lineberger Comprehensive Cancer Center","enrolled":45,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03977233/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"flot","kind":"drug","name":"FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)","route":"/drugs/flot/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"irinotecan","kind":"drug","name":"Irinotecan (and liposomal irinotecan)","route":"/drugs/irinotecan/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}